1. Home
  2. FFWM vs ADCT Comparison

FFWM vs ADCT Comparison

Compare FFWM & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Foundation Inc.

FFWM

First Foundation Inc.

HOLD

Current Price

$6.05

Market Cap

498.1M

Sector

Finance

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$3.30

Market Cap

439.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FFWM
ADCT
Founded
1990
2011
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
498.1M
439.8M
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
FFWM
ADCT
Price
$6.05
$3.30
Analyst Decision
Buy
Strong Buy
Analyst Count
3
6
Target Price
$6.17
$7.60
AVG Volume (30 Days)
637.5K
582.0K
Earning Date
01-29-2026
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$159,621,000.00
$75,209,000.00
Revenue This Year
$166.48
$12.48
Revenue Next Year
$6.86
$5.12
P/E Ratio
N/A
N/A
Revenue Growth
47.55
6.35
52 Week Low
$4.42
$1.05
52 Week High
$6.54
$4.80

Technical Indicators

Market Signals
Indicator
FFWM
ADCT
Relative Strength Index (RSI) 46.78 38.09
Support Level $5.89 $3.51
Resistance Level $6.28 $3.64
Average True Range (ATR) 0.21 0.21
MACD -0.04 -0.01
Stochastic Oscillator 18.46 0.54

Price Performance

Historical Comparison
FFWM
ADCT

About FFWM First Foundation Inc.

First Foundation Inc is a financial services company. It is engaged in providing investment management and financial planning services for high-net-worth individuals, retirement plans, charitable institutions, and private foundations. The company focuses on segments namely Banking and Wealth Management. It also offers loans to individuals and entities that own and operate multifamily residential and commercial real estate properties as well as business banking products and services to small to moderate-sized businesses, professional firms, and consumer banking products and services to individuals.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: